Update information

Update information

6 May 2022

We added new recommendations on baricitinib.

13 April 2022

We added a new recommendation on nirmatrelvir and ritonavir (Paxlovid) for people at high risk of progression to severe COVID-19.

30 March 2022

We updated existing recommendations on casirivimab and imdevimab - for people hospitalised because of COVID-19.

10 March 2022

We added a new recommendation on awake prone positioning and updated existing recommendations on non-invasive respiratory support.

23 February 2022

We added recommendations on molnupiravir and remdesivir for people with COVID-19 who do not need supplemental oxygen.

27 January 2022

We added recommendations on neutralising monoclonal antibodies for people with COVID-19 who are not in hospital.

16 December 2021

We added new recommendations on COVID-19-associated pulmonary aspergillosis. We revised our statement about the Omicron variant in the recommendation on casirivimab and imdevimab.

14 December 2021

We added a statement to the recommendation on casirivimab and imdevimab about the Omicron variant.

1 December 2021

We updated existing recommendations on colchicine.

22 November 2021

We added a new recommendation on ivermectin.

3 November 2021

We added a new recommendation on inhaled budesonide and updated the recommendations on casirivimab and imdevimab, clarifying that these recommendations apply to people who are hospitalised because of COVID-19.

27 October 2021

We updated existing recommendations on tocilizumab and sarilumab.

4 October 2021

We added new recommendations on casirivimab and imdevimab. We have also updated our supporting evidence on the use of heparins with the peer reviewed REMAP-CAP trial results. This update does not change our current recommendations.

2 September 2021

We added new recommendations on non-invasive respiratory support and doxycycline, and updated existing recommendations on heparins.

10 August 2021

We corrected an error in the practical info section of the recommendations on corticosteroids. The dose of prednisolone for children with a greater than 44-week corrected gestational age is 1 mg/kg.

We made minor changes to:

  • clarify that NHS England's Interim Clinical Commissioning Policy on remdesivir for patients hospitalised with COVID-19 was updated in June 2021 to include eligibility criteria for people who are significantly immunocompromised

  • update hyperlinks in the recommendations on communication and shared decision-making.

3 June 2021

We added new recommendations on azithromycin to treat COVID-19.

27 May 2021

We added new recommendations on colchicine to treat COVID-19 and updated existing recommendations on remdesivir for COVID-19 pneumonia.

We made a minor change to our recommendation on using pulse oximetry to identify people with severe COVID-19 in primary and community care settings to clarify that the NHS England guide should be followed for adults.

8 April 2021

We added recommendations for using corticosteroids, tocilizumab and sarilumab to treat COVID-19 (including the evidence and rationale for making the recommendations).

This updates and replaces our COVID-19 rapid evidence summaries on:

  • remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 (ES27, published 5 June 2020)

  • tocilizumab for COVID-19 (ES33, published 15 January 2021, last updated 24 February 2021)

  • sarilumab for COVID-19 (ES34, published 20 January 2021)

23 March 2021

This guideline updates and replaces our COVID-19 rapid guidelines on:

  • critical care in adults (NG159, published 20 March 2020, last updated 12 February 2021)

  • managing symptoms (including at the end of life) in the community (NG163, published 03 April 2020, last updated 13 October 2020)

  • managing suspected or confirmed pneumonia in adults in the community (NG165, published 03 April 2020, last updated 23 April 2020)

  • acute myocardial injury (NG171, published 23 April 2020)

  • antibiotics for pneumonia in adults in hospital (NG173, published 01 May 2020, last updated 09 October 2020)

  • acute kidney injury in hospital (NG175, published 06 May 2020)

  • reducing the risk of venous thromboembolism in over 16s with COVID-19 (NG186, published 20 November 2020).

The guideline includes new recommendations on the use of therapeutics for people with COVID-19.

Minor changes since publication

22 July 2021: we added a cross-reference to the Renal Association's guidelines on renal replacement therapy for critically unwell adults for information on managing renal replacement therapy for adults who are critically unwell with COVID-19

ISBN: 978-1-4731-4074-5